Business Wire

Mary Kay Europe Wins Bronze at 2018 Brandon Hall Group Excellence Awards in Technology

Del

Brandon Hall Group, one of the most well-known and established research organizations in the performance improvement industry, recognized Mary Kay with a coveted Brandon Hall Group Bronze award for excellence in the category of Best Advance in Learning Management Technology for External Training.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190110005091/en/

This innovative e-learning platform connects Mary Kay Independent Beauty Consultants to a learning c ...

This innovative e-learning platform connects Mary Kay Independent Beauty Consultants to a learning community based on content, accessibility and localization. (Graphic: Mary Kay Inc.)

The award honored the beauty company’s new, innovative Link & Learn™ global sales education system. A panel of veteran, independent senior industry experts alongside Brandon Hall Group analysts and executives evaluated the entries. The award winners will be honored at the Human Capital Management Excellence Conference hosted by Brandon Hall in West Palm Beach Florida in January.

Mary Kay Independent Beauty Consultants in nine European markets are among the first to experience the robust learning curriculum designed to amplify educational support for the independent sales force and increase their business success. The innovative e-learning platform connects Mary Kay Independent Beauty Consultants to a learning community based on content, accessibility and localization.

“Mary Kay fosters a culture of innovation and we are honored to receive the 2018 Brandon Hall Group Bronze award for the hard work put into the launch of our Link & Learn™ technology,” said Beth Lopez, Vice President of Global Sales Education for Mary Kay and Vice President of Sales and Marketing for Mary Kay Inc.’s European Region. “Reaction and engagement to the new sales education system has been overwhelmingly positive and we will continue to work with our Mary Kay markets to roll out this innovative, award-winning platform to help continue our mission of enriching women’s lives around the world.”

Brandon Hall Group Excellence Awards in Technology recognize organizations that have successfully deployed programs, strategies, modalities, processes, systems and tools that have achieved measurable results. Entries for the awards are based upon criteria including breakthrough innovation, unique differentiators and value proposition.

“We’re proud to honor the innovators. As human capital management continues to evolve, the creativity of the award winners is breathtaking,” said Rachel Cooke, Chief Operating Officer of Brandon Hall Group and Head of the Awards Program. “Organizations of all sizes showed that creativity and technology can create new and better work experiences.”

For a complete list of Brandon Hall Group award winners, click here.

About Mary Kay

At Mary Kay, success lies in our dedication to irresistible products, a rewarding opportunity and positive community impact. For 55 years, Mary Kay has inspired women to achieve their entrepreneurial goals in nearly 40 countries. As a multibillion-dollar company, we offer the latest in cutting-edge skin care, bold color cosmetics and fragrances. Discover more reasons to love Mary Kay at marykay.com.

About Brandon Hall Group, Inc.

With more than 10,000 clients globally and 20 years of delivering world class research and advisory services, Brandon Hall Group is the most well-known and established research organization in the performance improvement industry. We conduct research that drives performance and provides strategic insights for executives and practitioners responsible for growth and business results. Brandon Hall Group has an extensive repository of thought leadership, research and expertise in Learning and Development, Talent Management, Leadership Development, Talent Acquisition and Human Resources. At the core of our offerings is a Membership Program that Empowers Excellence Through Content, Collaboration and Community. Our members have access to research that helps them make the right decisions about people, processes, and systems, combined with research-powered advisory services customized to their needs. For more information, visit www.brandonhall.com

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Fishawack continues to build best-in-class service offering with Dudnyk acquisition20.3.2019 13:00:00 CETPressemelding

Fishawack, a leading independent healthcare communications specialist, is excited to announce its acquisition of Dudnyk, the Philadelphia-based healthcare communications agency. Dudnyk is an award-winning, full-service agency that specializes in creating insight-driven, authentic brand experiences that unite specialty physicians and their patients. They leverage strategic, scientific, and creative capabilities to serve clients in the biotech, pharmaceutical, and medical device industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190320005204/en/ Dudnyk leadership team includes Christopher Tobias, PhD, President; Laurie Bartolomeo, EVP, Creative Director; Drew Desjardins, EVP, Chief Strategy Officer; Annemarie Armstrong, EVP, Director of Client Services; John Kemble, EVP, Creative Producer. (Photo: Business Wire) Fishawack’s goal is to increase the range of healthcare communications services that it can offer to commerc

ExaGrid Nominated in Six Categories for the 2019 Network Computing Awards20.3.2019 12:00:00 CETPressemelding

ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been nominated in six categories for the 2019 Network Computing Awards. ExaGrid has become a finalist for Data Centre Product of the Year, The Return on Investment Award, Hardware Product of the Year, Product of the Year, The Customer Service Award, and Company of the Year. Voting to determine the winner in each category is underway now and closes on April 23. The results will be revealed at an evening award ceremony in London on May 2. ExaGrid’s model EX63000E backup storage appliance with data deduplication is a nominee in four categories. The model provides the largest scale-out system and offers up to a 2PB full backup with an ingest rate of 432TB/hr, which is three times faster than any other backup storage on the market. “We are thrilled to be nominated by IT staff, and recognized by Network Computing, in six prestigious categories this year,” said Bill Andrews, CEO and Pre

Eos Biosciences Issued Patent for New Approach to Shuttle Therapeutics Across the Blood-Brain Barrier to Treat Brain Diseases20.3.2019 11:30:00 CETPressemelding

Eos Biosciences, Inc. (Eos), a nanomedicines company developing an efficient and versatile nanobiologic particle-based platform technology (Eosomes), announced that the U.S. Patent and Trademark Office has granted Eos Biosciences Patent No. 10,183,078, relating to a novel approach of using HER3-targeted Eosomes as a shuttle system for transporting various classes of therapeutics across the blood-brain barrier for treatment of brain disorders, including brain cancer. The patent is owned by Cedars-Sinai Medical Center and is exclusively licensed to Eos Biosciences. Details of the system will be highlighted in an upcoming manuscript from Lali Medina-Kauwe, PhD, Professor, Department of Biomedical Sciences, Cedars-Sinai. Omar Haffar, Ph.D., Founder, President and Chief Executive Officer, commented, “We’re very excited by the issuance of this pivotal patent and look forward to receiving similar approvals in other countries. This patent adds to Eos’ considerable IP portfolio covering the Eos

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics20.3.2019 10:45:00 CETPressemelding

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease. Wilson disease is a devastating, rare, chronic, and potentially life-threatening liver disorder of impaired copper transport that causes serious copper poisoning. In patients with Wilson disease, a monogenetic mutation disables the normal copper biliary excretion pathway leading to excess copper accumulation in the liver and other organs including the central nervous system. Untreated, Wilson disease results in various combinations and severity of hepatic (fibrosis and cirrhosis), neurologic and psychiatric symptoms, which can b

Fintech Company Rimilia Appoints Kevin Kimber as CEO20.3.2019 10:00:00 CETPressemelding

Rimilia, a fintech company helping finance departments simplify the complex, has appointed Kevin Kimber as CEO. The news follows another strong year for Rimilia. In 2018, Rimilia opened offices in Central London and Denver, Colorado in the U.S., and reported significant revenue growth on the previous year. Rimilia was founded in 2008 and its platform, created by finance professionals, uses RPA (robotic process automation) technology to help finance teams fast-track their cash flow by providing clearer information and better control. It has quickly become the industry leader, trusted by a number of global brands from HSBC to DHL and Santander, to provide visibility, improve efficiencies and guarantee cash flow. Rimilia works with any currency, any bank and in any language, and on average delivers 70% cost-savings and an 80% reduction in manual effort to its customers. Kevin joins Rimilia from Eight Roads Ventures (one of Rimilia’s investors), where he was a Venture Partner, advising its

Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma20.3.2019 10:00:00 CETPressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet need, today announced a collaboration with a consortium of leading medical researchers in the United Kingdom to evaluate the ability of Knopp’s lead drug candidate, dexpramipexole, to reduce exacerbations in people with severe eosinophilic asthma. The project is chiefly funded by the National Institute for Health Research (NIHR) and Medical Research Council (MRC) of the UK. The Chief Investigator for the Phase 2 multi-center, 52-week trial is Professor Salman Siddiqui, Professor of Airway Diseases at the University of Leicester and Consultant Respiratory Physician at Leicester’s Hospitals. Dexpramipexole is an orally available small molecule shown to selectively reduce eosinophil levels in multiple clinical trials, including in a Phase 2 study in hypereosinophilic syndrome (HES) and a Phase 2 trial in chr